Objective To evaluate the myocardial protection effects of trimetazidine during percutaneous coronary intervention (PCI). Methods 101 patients from 5 hospitals with stable or unstable angina pectoris were enrolled in this study. All the patients were randomized into two groups: a trimetazidine group (n = 54) and a control group ( n = 47). The trimetazidine group received oral trimetazidine 20 mg three times a day for (5±2 ) days before coronary angiography and a loading dose of 60 mg 30 minutes before PCI. The daily routine dosage was continued for 4 weeks after the procedure. The control group received similar treatment except trimetazidine. For each patient, the angina pectoris attacks, CK-MB,electrocardiogram and echocardiogram were noted. Results Angina did not occur in trimetazidine group during the procedure but occurred in 12 patients( 25.5% ) in the control group( P <0.001 ). The changes of ST-segment and T wave during balloon dilatation in PCI procedure were less in the trimetazidine group (60.8% vs 78.3% , P < 0.05). Ejection fraction in the trimetazidine group was higher than that in the control group 4 weeks [ ( 66.6±7.1 ) % vs ( 63.0±7.7 ) % , P = 0.03 ] after PCI. Conclusion Trimetazidine could reduce the frequency of angina pectoris attacks and myocardial damage during PCL It also improves left ventricular function during follow-up after PCL

Objective To investigate the expression and significance of matrix metalloproteinases (MMPs) and toll-like receptor 9 (TLR9) in patients with acute leukemia. Methods A total of 44 patients with acute lymphoblastic leukemia (ALL) were enrolled in the ALL group, 30 patients with acute myeloid leukemia (AML) were included in AML group, and 44 healthy individuals undergoing physical examination during the same period were included in the control group. Serum levels of MMP-2, MMP-7, and MMP-9 were measured by enzyme-linked immunosorbent assay (ELISA) in all three groups. The expression of TLR9 mRNA and TLR9 protein in peripheral blood mononuclear cells (PBMCs) was detected by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot, respectively. Spearman's rank correlation analysis was used to explore the correlations of the malignancy of different clinical subtypes of acute leukemia with the expression levels of MMPs and TLR9 protein. Results Serum levels of MMP-2, MMP-7, and MMP-9 were significantly higher in the ALL and AML groups compared to the control group, with the AML group showing higher levels than the ALL group (P < 0.01). The relative expressions of TLR9 mRNA and TLR9 protein in PBMCs in both the ALL and AML groups were significantly lower than those in the control group, and the AML group had lower expression than the ALL group (P < 0.01). Spearman's rank correlation analysis revealed positive correlations of serum levels of MMP-2, MMP-7, and MMP-9 with the malignancy of both ALL and AML (P < 0.05), while the relative expression of TLR9 protein was negatively correlated with the malignancy of both ALL and AML (P < 0.05). Conclusion Serum levels of MMP-2, MMP-7, and MMP-9 are significantly elevated in patients with acute leukemia, while TLR9 expression is significantly reduced in PBMCs. The abnormal overexpression of MMPs may promote extramedullary infiltration and immune escape of acute leukemia cells by inhibiting TLR9 expression, thereby accelerating the malignant progression of the tumor.

Objective: To examine the impact of metabolic syndrome (MS) on the clinicopathological characteristics and prognosis of patients with colorectal cancer (CRC). Methods: The clinical data of 650 patients with CRC admitted in Shanxi Provincial Cancer Hospital between January 2010 and December 2011 were retrospectively analyzed. Among 650 patients there were 190 cases complicated with MS (MS group) and 460 cases without MS (non-MS group), the clinicopathological features and prognosis were compared between two groups. Results: The serum insulin and insulin-like growth factor-1 (IGF-1) levels in MS group were significantly higher than those in non-MS group [(9.2±4.7) vs.(6.8±4.7)μIU/L, t=8.88, P<0.01 and (200.2±44.1) vs.(136.7±63.2)mg/L,t=12.63, P<0.01]. The proportions of stage T₃ and T₄ cancer, extra-regional lymph node metastasis (ELN), and TNM stage Ⅲ and Ⅳ patients in MS group were significantly higher than those in non-MS group [(83.2% (158/190) vs. 72.6% (334/460), χ²=8.19, P=0.04; 9.5% (18/190) vs. 4.8%(22/460),χ²=8.61, P=0.04; 56.3% (107/190) vs. 45.2%(208/460), χ²=8.22, P=0.04, respectively]. The 5-year disease-free survival (DFS) in MS group was significantly lower than that in non-MS group [57.9%(99/171)vs. 66.1%(279/422), P<0.01]. Multivariate analysis indicated that MS(HR=1.623, 95%CI:1.511-1.963, P=0.03), IGF(HR=1.382, 95%CI:1.031-1.765, P=0.02) and, ELN(HR=4.270, 95%CI:2.177-7.463, P<0.01)were independent factors affecting the prognosis of CRC patients. Conclusion Metabolic syndrome is one of the risk factors affecting the prognosis of CRC patients.

Objective    To investigate the correlation between histological subtypes of invasive lung adenocarcinoma and epithelial growth factor receptor (EGFR) gene mutation, and to provide a reference for clinical prediction of EGFR gene mutation status. Methods    From October 2017 to May 2019, 102 patients with invasive lung adenocarcinoma were collected, including 58 males and 44 females aged 62 (31-84) years. Invasive lung adenocarcinoma was classified into different histological subtypes. Scorpion probe amplification block mutation system (ARMS) real-time PCR was used to detect the mutation of EGFR gene in adenocarcinoma specimens, and the relationship between invasive lung adenocarcinoma subtypes and EGFR mutation status was analyzed. Results    In 102 patients with invasive lung adenocarcinoma, EGFR gene mutations were detected in 68 patients, and the mutation rate was 66.7% (68/102). The mutation sites were mainly concentrated in the exons 19 and 21; the mutation rate was higher in female patients (34/44, 77.3%) and non-smokers (34/58, 58.6%). EGFR mutation was mostly caused by acinar-like invasive lung adenocarcinoma, and was rare in solid-type lung adenocarcinoma. The EGFR gene mutation rates in different subtypes of adenocarcinoma were statistically different (P<0.05). Conclusion    The EGFR mutation status is related to gender, smoking status and histological subtype of invasive lung adenocarcinoma. EGFR mutation rates are higher in female, non-smoking and acinar-like invasive lung adenocarcinoma patients, and are lower in patients with solid type lung adenocarcinoma.